Nilemdo 180 mg film-coated tablets, Obicetrapib, Obicetrapib matching placebo, Bempedoic acid matching placebo
AMIL/25/Obi-Dys/001
Phase 3 small_molecule active
Quick answer
Nilemdo 180 mg film-coated tablets, Obicetrapib, Obicetrapib matching placebo, Bempedoic acid matching placebo for Dyslipidemia at High to Very High Cardiovascular Risk is a Phase 3 program (small_molecule) at Menarini International Operations Luxembourg S.A. (MIOL) with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Menarini International Operations Luxembourg S.A. (MIOL)
- Indication
- Dyslipidemia at High to Very High Cardiovascular Risk
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active